{
  "id": 1767514228920,
  "title": "AION & GIANT CELL ARTERITIS: THE CLINICAL ESSENTIALS",
  "summary": "Anterior Ischaemic Optic Neuropathy (AION) is a major cause of acute vision loss in patients over 50. This guide provides an exhaustive breakdown of diagnostic criteria, emergency management for Giant Cell Arteritis (GCA), and the surgical approach for temporal artery biopsy.",
  "date": "2026-01-04T08:10:28.920Z",
  "data": {
    "title": "AION & GIANT CELL ARTERITIS: THE CLINICAL ESSENTIALS",
    "summary": "Anterior Ischaemic Optic Neuropathy (AION) is a major cause of acute vision loss in patients over 50. This guide provides an exhaustive breakdown of diagnostic criteria, emergency management for Giant Cell Arteritis (GCA), and the surgical approach for temporal artery biopsy.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='40' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='4'/><path d='M50 20 L50 45 M50 55 L50 80 M20 50 L45 50 M55 50 L80 50' stroke='red' stroke-width='2'/><circle cx='50' cy='50' r='12' fill='hsl(215, 90%, 45%)' opacity='0.8'/><path d='M35 35 L65 65 M65 35 L35 65' stroke='white' stroke-width='3'/></svg>",
    "sections": [
      {
        "title": "AION: Epidemiology & Vascular Supply",
        "icon": "visibility",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Anterior ischaemic optic neuropathy is a significant cause of acute visual loss in the elderly population, affecting up to 10/ 100,000/ y of those over 50y. In 5– 10%, the aetiology is arteritic, in which the majority of these are caused by GCA, and in 90– 95%, the aetiology is non- arteritic (see Table 16.5). The vascular supply to the anterior optic nerve is from the short posterior ciliary artery and the choroidal circulation."
      },
      {
        "title": "Arteritic vs. Non-arteritic AION Comparison",
        "icon": "compare",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Feature",
            "Arteritic AION",
            "Non-arteritic AION"
          ],
          "rows": [
            [
              "Incidence/ y",
              "1/ 100,000",
              "10/ 100,000"
            ],
            [
              "Cause/ possible associations",
              "Major: GCA. Minor: Churg– Strauss, PAN, GPA, RA, Relapsing polychondritis, Other connective tissue disorders (e.g. SLE)",
              "Major: Hypertension, Diabetes, Disc morphology ‘disc at risk’. Minor: Smoking, Hyperlipidaemia, Acute hypotension, Anaemia, Obstructive sleep apnoea, Optic disc drusen, Cataract surgery, Non- ocular surgery (e.g. cardiac, spinal), Drugs (e.g. amiodarone, erectile dysfunction drugs), Radiation- induced optic neuropathy"
            ],
            [
              "Age (mean)",
              "70y",
              "60y"
            ],
            [
              "VA + VF",
              "Sudden d, Usually <6/ 60",
              "Sudden d, Usually >6/ 60, Often altitudinal field loss"
            ],
            [
              "Associated symptoms",
              "Scalp tenderness, jaw claudication, headache",
              "Usually none"
            ],
            [
              "Disc",
              "Swollen, Commonly pale",
              "Swollen (often sectoral), Commonly hyperaemic, Predisposed (small + crowded)"
            ],
            [
              "ESR ii",
              "Mean = 70mm/hr",
              "Normal"
            ],
            [
              "CRP ii",
              "Increased",
              "Normal"
            ],
            [
              "Platelet i",
              "Increased",
              "Normal"
            ],
            [
              "Risk to fellow eye",
              "10% (if treated) to ≤95% (untreated)",
              "Not provided in comparison table"
            ],
            [
              "Prognosis",
              "Up to 15% improve",
              "40% improve (by ≥2 Snellen lines)"
            ]
          ]
        }
      },
      {
        "title": "Giant Cell Arteritis (GCA) Essentials",
        "icon": "emergency",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "GCA or temporal arteritis is an ophthalmic emergency.",
          "Requires immediate assessment and systemic corticosteroid treatment.",
          "Mean onset is 70y; rare before 50y.",
          "Commonly occurs in Caucasians; 3x more likely in ♀.",
          "Pathology: Short posterior ciliary artery vasculitis leads to ischaemic necrosis of the optic nerve head.",
          "Clinical judgement is required due to disease heterogeneity."
        ]
      },
      {
        "title": "GCA Clinical Features",
        "icon": "clinical_notes",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Sudden dVA (<6/ 60 in 76%).",
          "New- onset headache, scalp tenderness, jaw claudication, weight loss, night sweats, myalgia (association with PMR).",
          "Warning episode: Transient dVA (short obscurations or longer amaurosis fugax- like episodes).",
          "Signs: RAPD, swollen disc (typically pale; rarely segmental) ± peripapillary haemorrhages and CWS.",
          "Abnormal temporal arteries: Thickened, tender, non- pulsatile.",
          "Associations: CRAO, BRAO, cilioretinal artery occlusion; III, IV, VIn palsy."
        ]
      },
      {
        "title": "Traditional Diagnosis Criteria (Box 16.2)",
        "icon": "fact_check",
        "type": "remember",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": {
          "mnemonic": "GCA DIAGNOSIS (Hunder GG et al)",
          "explanation": "3+ criteria = 93.5% sensitivity/91.2% specificity: 1. Age ≥50y. 2. New onset localized headache. 3. Temporal artery tenderness or dpulse. 4. ESR ≥50mm/ h (Westerngren). 5. Arterial biopsy showing necrotizing arteritis with mononuclear cell infiltrates or granulomatous process with multinuclear giant cells."
        }
      },
      {
        "title": "Investigations Strategy",
        "icon": "biotech",
        "type": "process",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "1. Immediate Bloods: ESR, CRP, FBC (iESR, iCRP, and iPlt support GCA).",
          "2. Prompt TAB: Recommended length ≥2cm, no <1cm. Aim within 1wk (positive up to 2– 6wk post-treatment).",
          "3. Additional: U+E, LFTs, CXR, and urinalysis.",
          "4. Long term: 2- yearly CXR for aneurysm detection (suspected large-vessel GCA)."
        ]
      },
      {
        "title": "Diagnostic Imaging & Specialized Tests",
        "icon": "biomedical_extraction",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Duplex US: Hypoechoic ‘halo’ (vessel wall oedema) + stenosis/occlusion. User-dependent; positive >2wk post-steroids.",
          "Fluoro- deoxyglucose PET: Assessing disease activity/extent, especially in large-vessel vasculitis.",
          "High- resolution MRI: Superficial cranial/extracranial arteries (not routinely performed)."
        ]
      },
      {
        "title": "Emergency Treatment Protocol",
        "icon": "medical_services",
        "type": "process",
        "layout": "full_width",
        "color_theme": "green",
        "content": [
          "1. Immediate systemic corticosteroids: e.g. 1g IVMP 1×/ d for 1– 3d.",
          "2. Oral Follow-up: PO prednisolone 1– 2mg/ kg 1×/ d.",
          "3. Patient Counseling: Mandatory explanation of side effects (gastric/bone protection required).",
          "4. Titration: Once controlled, titrate by symptoms and markers (CRP responds faster than ESR).",
          "5. Specialist Referral: Seek rheumatologist if comorbidities complicate therapy.",
          "6. Emerging Agents: Tocilizumab (IL-6 receptor antagonist) inducing sustained remission at 1yr. Leflunomide under investigation."
        ]
      },
      {
        "title": "Management of Negative TAB",
        "icon": "rule",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": "If there is a typical clinical/laboratory picture and positive steroid response despite negative TAB, manage as GCA. If history and markers are atypical with negative TAB, consider alternative diagnoses and specialist referral. Steroids can be rapidly tapered within 2wk."
      },
      {
        "title": "Differential Diagnosis of GCA",
        "icon": "list_alt",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "GPA",
          "PAN",
          "SLE",
          "RA",
          "Takayasu arteritis"
        ]
      },
      {
        "title": "Prognosis & Systemic Risks",
        "icon": "warning",
        "type": "red_flag",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "Risk to fellow eye: 10% if treated; up to 95% if untreated.",
          "TIA and Stroke",
          "Myocardial infarcts",
          "Neuropathies",
          "Mesenteric artery occlusion",
          "Thoracic artery aneurysms",
          "Death"
        ]
      },
      {
        "title": "Surgical Approach: Superficial TAB (Box 16.3)",
        "icon": "content_cut",
        "type": "process",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "Preoperative: Choose side of visual loss/abnormality. Map artery by palpation or US Doppler. Mark skin. Hair removal.",
          "Procedure - Cleaning & LA: Clean skin. Infiltrate LA (27G). Adrenaline optional (helps haemostasis/visualization).",
          "Procedure - Incision: Parallel to Langer's lines. Blunt dissection (do not breach superficial temporalis fascia).",
          "Procedure - Ligation: Tie 4- 0 silk/Vicryl twice at distal/proximal ends. Pass needle backwards or double suture without needle. Ligate local tributaries.",
          "Procedure - Specimen Care: Do not crush by regrasping specimen. Maximize biopsy length.",
          "Procedure - Closure: Subcutaneous (5- 0 interrupted Vicryl). Skin (running 6- 0 Vicryl subcuticular).",
          "Post-operative: Compression bandage for 24h. Optional antibiotic ointment for 3– 4d."
        ]
      },
      {
        "title": "References & Footnotes",
        "icon": "menu_book",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "14. Dasgupta B et al. BSR and BHPR guidelines for management of GCA. Rheumatology (Oxf). 2010;49:1594– 7. 15. Hunder GG et al. ACR 1990 criteria for classification of GCA. Arthritis Rheum 1990;33:1122– 8. 16. Dasgupta B et al. BSR and BHPR guidelines. Rheumatology (Oxf). 2010;49:1594– 7. Note: ESR ii = significantly increased; Platelet i = increased."
      }
    ]
  },
  "chapterId": "neuro",
  "seqId": 90
}